Knight Therapeutics Inc. (TSX:GUD)
7.58
-0.04 (-0.52%)
Apr 14, 2026, 4:00 PM EST
Knight Therapeutics Revenue
In the year 2025, Knight Therapeutics had annual revenue of 450.09M CAD with 21.22% growth. Knight Therapeutics had revenue of 133.11M in the quarter ending December 31, 2025, with 37.42% growth.
Revenue
450.09M
Revenue Growth
+21.22%
P/S Ratio
1.66
Revenue / Employee
542.27K
Employees
830
Market Cap
747.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 450.09M | 78.78M | 21.22% |
| Dec 31, 2024 | 371.30M | 43.11M | 13.13% |
| Dec 31, 2023 | 328.20M | 34.64M | 11.80% |
| Dec 31, 2022 | 293.56M | 50.09M | 20.57% |
| Dec 31, 2021 | 243.48M | 43.96M | 22.03% |
| Dec 31, 2020 | 199.52M | 152.06M | 320.39% |
| Dec 31, 2019 | 47.46M | 34.96M | 279.69% |
| Dec 31, 2018 | 12.50M | 3.87M | 44.78% |
| Dec 31, 2017 | 8.63M | 2.69M | 45.35% |
| Dec 31, 2016 | 5.94M | 4.90M | 472.81% |
| Dec 31, 2015 | 1.04M | 672.00K | 184.11% |
| Dec 31, 2014 | 365.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Trulieve Cannabis | 1.62B |
| Green Thumb Industries | 1.61B |
| Verano Holdings | 1.13B |
| Cresco Labs | 899.24M |
| Aurora Cannabis | 373.12M |
| TerrAscend | 357.26M |
| Organigram Global | 279.99M |
| Canopy Growth | 278.39M |
Knight Therapeutics News
- 22 days ago - Knight Amends Normal Course Issuer Bid - GlobeNewsWire
- 26 days ago - Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results - GlobeNewsWire
- 4 weeks ago - Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call - GlobeNewsWire
- 7 weeks ago - Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil - GlobeNewsWire
- 4 months ago - Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris - GlobeNewsWire
- 5 months ago - Knight Therapeutics Reports Third Quarter 2025 Results - GlobeNewsWire
- 5 months ago - Knight Announces Closing of US$100 Million Revolving Credit Facility - GlobeNewsWire
- 5 months ago - Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call - GlobeNewsWire